SlideShare a Scribd company logo
DIAGNOSIS AND MANAGEMENT
OF
SYSTEMIC LUPUS ERYTHEMATOSUS
A PRESENTATION BY DR. ASHVINI K. LOMROD
UNDER THE GUIDANCE OF DR. C.K. MEENA SIR
JLN MEDICAL COLLEGE, AJMER
Systemic+ Lupus+ Erythematosus
Systemic - The disease can affect organs and tissues throughout the
body.
Lupus [ Latin for wolf ] It refers to the rash that was thought to
resemble a wolf bite.
Erythematosus [ Greek word for red ] – It refers to the color of the
rash.
DEFINITION
•A systemic autoimmune disease with relapsing
and remitting course that can affect almost any
organ system in which organs and cells undergo
damage mediated by tissue binding
autoantibodies and immune complexes.
RISK FACTORS
➢ Gender – 90% women(women to men ratio 9:1) in child bearing age. Flares
also become some what less common after menopause in women have chronic
SLE.
Female sex is permissive for SLE because:
- Hormone effects
- Genes on X-chromosome
-Epigenetic differences between genders
Estradiol binds to receptors on T & B lymphocytes increasing activation &
survival of these cells, thus favouring prolonged immune response.
So women are exposed to estrogen containing OCP and hormone replacement
therapy have an increased risk of developing SLE.
People with more X-chromosomes(XXX karyotypes,Klinefelter’s syndrome)
have a significant increased risk for SLE.
➢ Age – 15-44 yrs are commonly affected.
➢Race & Ethnicity – More common in urben than rural areas.
Highest prevalence is in black women and lowest
is in white men.
➢ Family History - A brother or sister of a patient with the disorder
has 20 times the risk as someone without an
immediate family member with SLE.
➢Environmental Triggers – Sunlight, cold, fatigue, stress, chemicals and
certain drugs.
*Sunlight : Ultraviolet rays (UVB or UVA) Shorter UVB wavelengths cause
the most harm.
*Viruses : EBV ( The cause of mononucleosis)
*Smoking : May increase the risk for skin and kidney problems in women
who have the disease.
*Tobacco
*Chemicals: Occupational exposure to crystalline silica as a possible trigger.
Some prescription medications are associated with a temporary
lupus syndromes (drug-induced lupus),which resolves after these
drugs are stopped.
☻ Drinking alcohol(2 glasses of wine a week or ½ of an alcoholic drink daily)
reduces the risk of SLE.
* Hormone Replacement Therapy : increases the risk for blood clots and
heart problems as well as breast cancer.
Guidelines recommend HRT the lowest possible dose for the shortest
possible time. Women with SLE who have active disease, antiphospholipid
Antibodies or a history of blood clots or heart disease should not use HRT.
* Oral Contraceptives : Caution against taking OCPs( Estrogen could
trigger lupus flare-ups).However, recent evidence indicate that OCs are
safe, at least for women with inactive or stable lupus. Lupus can cause
complications in its early stages. The estrogen in OCs increase the risk for
blood clots.(Risk particularly for women with antiphospholipid syndrome)
Different forms of LUPUS
➢ SLE - The most common type and is the type of lupus that
can lead to serious systemic complications.
➢ Cutaneous lupus erythematosus - Confined to the skin
and does not affect other parts of the body. About 10% of
people with this type of lupus go on to develop SLE.
➢ Discoid lupus erythematosus - A type of cutaneous lupus
that produces a potentially scarring disc shaped rash on the
face, scalp or ears.
➢ Drug-induced lupus - Temporary and mild form of lupus
due to some drugs like Hydralazine, ACE inhibitors, and
calcium channel blockers, hydrochlorothiazide. Symptoms
resolve once the medication is stopped.
➢ Neonatal lupus - A rare condition that sometimes affects
infants born to mothers who have SLE. Babies with
neonatal lupus are born with skin rash, liver problems, and
low blood counts and may develop heart problems.
ETIOPATHOLOGY
Role of Genetics and Environment
➢Environment
• Cell damage by environmental triggers causes apoptosis that leads to release of
apoptotic bodies+parts of nucleus [ now exposed to other parts of body ]
➢ Genetics – Susceptibility genes and their effect on immune system.
• loss of self tolerance [ immune system recognizes parts of nucleus as self antigens ]
• Self Ag presentation by DCs,
• Defective complement system,
• Impaired clearance of apoptotic cells
• Aberrant lymphocyte activity[unregulated T cell dependent B cell activation]
• Production of autoantibodies
• Antigen-Antibody complexes / Immune Complexes deposition in various body tissues
[ basement membranes ] results
– Local inflammation
– Local complement activation
– Local apoptosis
– Positive feedback loop
• DNA is the main antigen for which antibodies are formed
• IgG is the most “pathogenic” because it forms intermediate sized complexes that can get
to the small places and block them
• Injury is caused by
Mainly deposition of immune complexes and
Binding of antibodies to various cells and tissues.
• In most patients, autoantibodies are present for a few years before the first clinical
symptom appears
Ag, antigen; C1q, complement system; C3, complement component; CNS, central nervous system; DC, dendritic
cell; EBV, Epstein-Barr virus; HLA, human leukocyte antigen; FcR, immunoglobulin Fc-binding receptor; IL,
interleukin; MCP, monocyte chemotactic protein; PTPN, phosphotyrosine phosphatase; UV,ultraviolet.
CLINICAL MENIFESTATIONS
TYPICAL PRESENTATION
Constitutional
• Fatigue – Mild to extreme
• Malaise
• Fever – any pattern
• Anorexia
• Weight loss
• lymphadenopathy
• Arthralgia
Musculoskeletal
• Arthralgia , myalgia
• Polyarthritis [ 2 or more peripheral joint ] - Intermittent,mild to disabling,soft tissue swelling,
tenderness,Nonerosive,MC in hands,wrists and knees
• Joint deformities (hands and feet)-In 10% cases ,erosions can be identified on ultrasound
(rarely on x-rays)
• Myopathy /myositis
• Ischemic necrosis of bone
“rhupus”-some patients of SLE have rheumatoid like arthritis with erosions and fulfill
criteria for both RA and SLE so may be coded having both diseases
JOINT DEFORMITIES
Cutaneous
• Photosensitivity-skin rash on Sun exposed areas due to sunlight
• Malar rash –MC acute SLE rash-photosensitive,slightly raised erythema,occasionaly scally,
on the face(butterfly rash-malar eminences and nasal bridge)but sparing nasolabialfold,
ears,chin,neck and chest,upper backand extensor surfaces of the arms
• Discoid rash (DLE)-MC chronic dermatitis in lupus,lesions roughly circular with slightly
raised ,scaly hyperpigmented erythematous rims and depigmented,atrophic centers
(permanently damaged dermal appendages)
• Subacute cutaneous lupus
• Oral lesions-Erythema of palate,tongue and oral mucosa,papules,vesicles and petechiae.oral
or nasopharyngial ulceration usually painless
• Alopacia
• Others-urticaria,
• Vasculitis rash
• Raynodes phenomena
Types of
cutaneous
lupus
erythematosus
MALAR RASH
Photosensitive systemic lupus erythematosus (SLE) rashes typically occur on the face or extremities
which are sun exposed regions. Although the interphalangeal space are affected, the metacarpophalangeal
(MCP) and proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints are spared.
Hematologic
• Anemia of chronic disease-most frequent
• Hemolytic anemia
• Leukopenia (<4000/micro litre)
• Lymphopenia (<1500/micro litre)
• Throbocytopenia (<1,00,000/micro litre)
• Lympadenopathy
• Splenomegaly
Neurologic
• Cognitive disorder - MC manifestation of diffuse CNS lupus
• Mood disorder
• Headache
• Seizures
• Mono-,polyneuropathy
• Stroke,TIA
• Acute confusional state or movement disorder
• Aseptic meningitis , myelopathy
PULMONARY
• MC-Pleuritis with or
without pleural effusion –
Chest pain
• Lupus pneumonitis
• Interstitial fibrosis
• Pulmonary hypertension,
• ARDS, intraalveolar
Hemorrhage
• Shrinking lung syndrome
CARDIAC
• Pericarditis-most frequent cardiac
manifestation
• Myocarditis
• Fibrinous endocarditis of libman-sacks
(valvular vegetations)
• Accelerated atherosclerosis-10 times
higher mortality
• Coronary artery disease
• Aortic insufficiency- MC valvular lesion
Renal
• 50 % of lupus pts will have kidney involvement in their life ,of these 50 % will have
serious kidney disease
• Persistent proteinuria > 0.5 grams / 24 hrs (or greater than 3+), cellular casts ( may be
red cells ,hemoglobin,granular, tubular,mixed)
• Nephritis (Lupus nephritis) –the most serious manifestation and also predict outcome
(prognosis)
• Renal Failure because of Glomerulonephritis is the leading cause of death among lupus
patients.
• Nephrotic syndrome
• ESRD
GIT
• Nonspecific – Nausea, vomitting, diarrhea
• Diffuse abdominal pain-autoimmune peritonitis and/or intestinal vasculitis
• Abnormal liver enzymes (more often due to therapy than to
SLE itself)
• Mesenteric Vasculitis
• Sepsis and bleeding
Thromboembolic events
Patients of Antiphospholipid syndrome due to hypercoagulable state
more prone to clots [ venous or arterial ] that can leads to
• Deep vein thrombosis
• Hepatic vein thrombosis
• Stroke
• Myocardial infarction
Ocular
• Common but less serious - Sicca syndrome
Conjunctivitis
Episcleritis
• Serious manifestations - Retinal vasculitis
Optic neuritis
• Fundoscopy shows sheathed, narrow retinal arterioles and white
hard exudate called ‘Cytoid body’
LUPUS NEPHRITIS
LN-Treatment
In general, class III and IV disease, as well as class V accompanied by III or IV
disease, should be treated with aggressive immunosuppression if possible,
because there is a high risk for end-stage renal disease (ESRD) if patients are
untreated or undertreated.
In contrast, treatment for lupus nephritis is not recommended in patients with
class I or II disease or with extensive irreversible changes.
INVESTIGATIONS
AIMS
• Diagnosis of SLE
• Course of the disease
• Adverse effects of therapies
LABORATORY TESTS
• Antinuclear antibodies [ANA]-Sensitive but not specific
• Anti -ds DNA-[ More specific ], targets double-stranded DNA, seen during active disease
• 4 RNA associated antibodies -
Anti-Sm [Smith] –[ More specific ]Targets ribonucleoproteins
Anti Ro /SSA- antibody
Anti La/SSB- antibody
Anti –RNP
• Antiphopholipid antibody- [Less specific to Lupus] Targets protein bound to phospholipid
Lupus anticoagulent [ Lupus antibody ]
Anti-B2 glycoprotein 1 AB
Anti-cardiolipin
• Coombs test- Hemolytic anemia
.
• Complete blood count-Hemolytic anemia with reticulocytosis
Leukopenia-less than 4,000 / cu mm on 2 or more occasions
Lymphopenia-less than 1,500 / cu mm on 2 or more occasions
Thrombocytopenia-less than 100,000 /cu mm , in the absence of offending drugs
• Erythrocyte sedimentation rate
• RFT,LFT ,Lipid profile
• C-reactive protein
• Urine routine and microscopy and 24 hrs protein and creatinine estimation
• Complement levels [ C3 and C4 ] - Decreased (C3 level < 5.5 mg/dl)
• Chest radiography and chest CT scanning-
ILD, pneumonitis, pulmonary emboli, alveolar haemorrhages
• Joint radiograpy-periarticular osteopenia and soft tissue swelling without
erosions
• Echocardiography-pericardial effusion
• ↑ ESR, ↑ anti ds-DNA and ↓C3 may indicate disease ‘flare’
Skin Biopsy
LUPUS BAND TEST (60%)
Deposition of Ig at the dermoepidermal junction (DEJ), injury
to basal keratinocytes, and inflammation dominated by T
lymphocytes in the DEJ and around blood vessels and dermal
appendages. Clinically unaffected skin may also show Ig deposition
at the DEJ
Renal biopsy
• In the recent Systemic Lupus International Collaborating Clinic (SLICC)
criteria for classification of SLE, a diagnosis can be established on the
basis of renal histology alone without meeting additional criteria .
• The pattern and severity of injury are important in diagnosis and in
selecting the best therapy.
• Recommended for every SLE patient with any clinical evidence of
nephritis
• Not recommended as a screening test
Histologic abnormalities in blood vessels
• Leukocytoclastic vasculitis is most common.
• Not specific for SLE but may indicate active disease
Lymph node biopsies
• Nonspecific diffuse chronic inflammation.
• Usually performed to rule out infection or malignancies.
MANAGEMENT
• There is no cure for SLE and complete sustained remissions are
rare so management aims to induce remissions of acute flares ,
maintenance therapy and thereby preventing organ damage
• Many patients with SLE have “flares”, in which symptoms
suddenly worsen and then settle down for long periods of time.
Conservative management
• NSAIDs, salicylates (Ecotrin a and St. Joseph’s aspirin approved by FDA for use in SLE )
for arthritis / arthralgia- Doses toward upper limit of recommended range usually required
• Antimalarials(HCQ,CQ,quinacrine)-for dermatitis, arthritis, fatigue
• Systemic glucocorticosteroids( low dose)
• Belimumab
• lupus dermatitis-topical sunscreens [ SPF 15 at least ; 30+ preferred],antimalarials, topical
glucocorticoids and/or tacrolimus and systemic glucocorticoids with or without
mycophenolate for severe or unresponsive cases
Life threatening SLE
• Systemic glucocorticoids
• Cytotoxic/immunosuppressive therapy
Systemic glucocorticoids
• MPS and Prednisolone
MPS 500-1000 mg IV over 1 hour OD for 3 days
followed by
0.5 - 1 mg/kg per day prednisolone PO
Currently
0.5 - 1 mg/kg per day prednisolone PO for 4-6 weeks therefore tappered as soon as
condition improves usually to a dose 5-10 mg daily
0.07–0.3 mg/kg prednisolone per day or qod for milder disease
Cytotoxic/immunosuppressive therapy
➢ Methotrexate
[for dermatitis, arthritis]
10–25 mg once a week, PO or SC, with folic acid; decrease dose if CrCl<60 mL/min
➢ Cyclophosphamide
• IV
Low dose : 500 mg every 2 weeks for 6 doses maintenance with MMF or
AZA. High dose: 7–25 mg/kg q month × 6; consider mesna administration
with dose
• Oral
1.5–3 mg/kg per day; decrease dose for CrCl <25 mL/min
• Mycophenolate
MMF: 2–3 g/d PO for induction therapy,
1–2 g/d for maintenance therapy; max 1 g bid if CrCl <25 mL/min
MPA: 360–1080 mg bid; caution if CrCl<25 mL/min
• Azathioprine
2–3 mg/kg per day PO for induction; 1–2 mg/kg per day for maintenance; decrease frequency
of dose if CrCl <50 mL/min
• Belimumab
10 mg/kg IV wks 0, 2, and 4, then monthly
• Rituximab
[ for patients resistant to above therapies ]
375 mg/m2 q wk × 4 or 1 g q 2 wks × 2
SERIOUS OR COMMON ADVERSE EFFECTS OF
DRUGS USED IN SLE
• NSAIDS-aseptic meningitis,elevated liver enzymes,decreased renal functions,vasculitis of
skin,MI,ototoxicity,tinitus,allergic reactions,dermatitis,gi events,ARF,edema,HTN
• Topical GC-skin atrophy,contact dermatitis,,folliculitis,hypopigmentation,infection
• Topical sunscreens-contact dermatitis
• HCQ-retinal damage,cornial opacity myopathy ,neuropathy
• MTX-megaloblastic anemia at low doses and bone marrow suppression at high doses
• GC-infections,HTN,hyperglycemia,hypokalemia,allergic reactions,cushingoid
changesCHF,fragile skin,menstrual abnormalities,osteoporosis
• MPS-same as gc; anaphylaxis
• Cyclophosphamide bone marrow suppression pancytopenia,hemorragic cystitis,ovarian
and testicular failure
• Mycophenolate –Vomiting diarrhoea and leukopenia
• Azathioprine –bone marrow suppression
• Rituximab - Infection (including PML), infusion reactions, headache, arrhythmias, allergic
responses
• Belimumab - Infusion reactions, allergy, infections probable
Lifestyle changes to help cope with SLE.
• Get plenty of rest (fatigue is another common SLE symptom)
• Salt restriction [ if HTN ] , avoid fat [ for hyperlipidaemia ] , calcium supplements with
steroid therapy
• Engage in regular light-to-moderate exercise to help fight fatigue and heart disease, and to keep
joints flexible
• Avoid excessive sunlight exposure, and wear sunscreen (ultraviolet light is the one of the main
triggers of flares)
• Don't smoke and avoid exposure to second-hand tobacco smoke
PREVENTIVE THERAPIES
Prevention of complications of SLE and its therapy
• Suppressing recurrent urinary tract infections.
• Providing appropriate vaccinations [ the administration of influenza and pneumococcal ]. [
Vaccination with attenuated live viruses is generally discouraged in patients who are
immunosuppressed ].
• Prevention of osteoporosis .
[ Postmenopausal women can be protected from steroid-induced osteoporosis
with either bisphosphonates or denosumab. Safety of long-term use of these
strategies in women is not well established ].
• Control of hypertension
• Prevention strategies for atherosclerosis
monitoring and treatment of dyslipidemias
management of hyperglycemia and obesity.
DIFFERENTIAL DIAGNOSIS
• Chronic fatigue syndrome
• Undifferentiated connective tissue disease
• Primary Sjogren`s syndrome
• Primary antiphospholipid syndrome
• Fibromyalgia with positive ANA
• Idiopathic thrombocytopenic purpura
• Drug-induced lupus
• Early RA
• Systemic vasculitis
SLE & PREGNANCY
• Increases the risk of spontaneous abortion, IUD, preeclampsia,IUGR and
preterm birth
• Prognosis best for both mother and child when SLE is quiescent for at least 6
months before the pregnancy and mothers renal function stable and normal
or near normal
• Lupus nephritis can get worse during pregnancy
• In general pregnancy does not cause flares of SLE
• When flares do develop ,they often occur during the first or second trimester
or during first few months after delivery
SPECIAL CONDITIONS IN SLE THAT MAY REQUIRE ADDITIONAL
OR DIFFEENT THERAPY
Crescentic Lupus Nephritis
The presence of cellular or fibrotic crescents in glomeruli with
proliferative glomerulonephritis indicates a worse prognosis Most
authorities currently recommend that high-dose cyclophosphamide is
the induction therapy of choice, in addition to high-dose
glucocorticoids.
Membranous Lupus Nephritis
Immunosuppression is not recommended unless proteinuria is in the
nephrotic range (although treatment with ACE inhibitors or angiotensin II
receptor blockers is recommended).
In those patients, recent prospective controlled trials suggest that alternate-
day glucocorticoids plus cyclophosphamide or mycophenolate mofetil or
cyclosporine are all effective in the majority of patients in reducing
proteinuria.
Pregnancy and Lupus
• Fertility rates for men and women with SLE are probably normal.
• Rate of fetal loss is increased (approximately two- to threefold) in women with SLE.
• Fetal demise is higher in mothers with high disease activity, antiphospholipid antibodies,
and/or active nephritis.
• Suppression of disease activity can be achieved by administration of systemic
glucocorticoids.
• Glucocorticoids [ Pregnancy category A (no evidence of teratogenicity in human studies)]
• Cyclosporine, tacrolimus, and rituximab [category C (may be teratogenic in animals but no
good evidence in humans) ];
• Azathioprine, hydroxychloroquine, mycophenolate mofetil, and cyclophosphamide
[category D (there is evidence of teratogenicity in humans, but benefits might outweigh
risks in certain situations) ];
• Methotrexate [ category X (risks outweigh benefits)].
• Therefore, active SLE in pregnant women should be controlled with hydroxychloroquine and,
if necessary, prednisone/prednisolone at the lowest effective doses for the shortest time required.
• Azathioprine may be added if these treatments do not suppress disease activity.
The cardiac manifestations can be life-threatening.
Recent evidence shows that hydroxychloroquine treatment of an anti-Ro-positive mother whose
infant develops congenital heart block significantly reduces the chance that subsequent fetuses
will develop heart block ,also with dexamethasone
A small proportion develops severe flares requiring aggressive glucocorticoid therapy or early
delivery.
Poor maternal outcomes are highest in women with active nephritis or irreversible organ
damage in kidneys, brain, or heart.
Lupus and Antiphospholipid Syndrome (APS)
• Patients with SLE who have venous or arterial clotting and/or repeated fetal losses and at
least two positive tests for antiphospholipid antibodies have APS
• Should be managed with long-term anticoagulation .
• A target international normalized ratio (INR) of 2.0–2.5 is recommended for patients with
one episode of venous clotting.
• An INR of 3.0–3.5 is recommended for patients with recurring clots or arterial clotting,
particularly in the CNS.
• Recommendations are based on both retrospective and prospective studies of post treatment
clotting events and adverse effects from anticoagulation.
Microvascular Thrombotic Crisis
(Thrombotic Thrombocytopenic Purpura, Hemolytic-Uremic Syndrome)
• This syndrome of hemolysis, thrombo cytopenia, and microvascular thrombosis in
kidneys, brain, and other tissues carries a high mortality rate and occurs most commonly in
young individuals with lupus nephritis.
• The most useful laboratory tests are identification of schistocytes on peripheral blood
smears, elevated serum levels of lactate dehydrogenase, and antibodies to ADAMS13
• Plasma exchange or extensive plasmapheresis is usually life-saving; most authorities
recommend concomitant glucocorticoid therapy; there is no evidence that cytotoxic drugs are
effective.
Lupus Dermatitis
• Minimize exposure to ultraviolet light [ appropriate clothing and sunscreens ] .
• Topical glucocorticoids and antimalarials (such as hydroxychloroquine) reduces lesion
severity in most patients and are relatively safe.
• Systemic treatment with retinoic acid is a useful strategy in patients with inadequate
improvement on topical glucocorticoids and antimalarials; adverse effects are potentially
severe (particularly fetal abnormalities),
• Extensive, pruritic, bullous, or ulcerating dermatitis usually improve promptly after
institution of systemic glucocorticoids; tapering may be accompanied by flare of lesions, thus
necessitating use of a second medication such as hydroxychloroquine, retinoids, or cytotoxic
medications such as methotrexate, azathioprine, or mycophenolate mofetil.
• Topical tacrolimus - In therapy-resistant lupus dermatitis [possible increased risk for
malignancies ] dapsone or thalidomide [ the extreme danger of fetal deformities ]
EXPERIMENTAL THERAPIES
➢ Highly targeted experimental therapies targeting
• (1) activated B lymphocytes with anti-CD22 or TACI-Ig,
• (2) inhibition of IFN-α,
• (3) inhibition of B/T cell second signal coactivation with CTLA-Ig,
• (4) inhibition of innate immune activation via TLR7 or TLR7 and 9,
• (5) induction of regulatory T cells with peptides from immunoglobulins or autoantigens;
• (6) suppression of T cells, B cells, and monocyte/macrophages with laquinimod; and
• (7) inhibition of lymphocyte activation by blockade of Jak/Stat. A few studies have used
vigorous untargeted immunosuppression with high dose cyclophosphamide plus anti-T
cell strategies, with rescue by transplantation of autologous hematopoietic stem cells for
the treatment of severe and refractory SLE. One U.S. report showed an estimated
mortality rate over 5 years of 15% and sustained remission in 50%.
DRUG-INDUCED LUPUS
• A syndrome of positive ANA associated with symptoms such as fever, malaise, arthritis or
intense arthralgias/myalgias, serositis, and/or rash, during therapy with certain medications
and biologic agents.
• Predominant in whites, has less female predilection than SLE.
• Rarely involves kidneys or brain.
• Rarely associated with anti-dsDNA.
• Commonly associated with antibodies to histones.
• Usually resolves over several weeks after discontinuation of the offending medication.
The most frequent drugs –
• Antiarrhythmics procainamide, disopyramide, and propafenone;
• Antihypertensive hydralazine;
• Angiotensin-converting enzyme inhibitors and beta blockers;
• Antithyroid propylthiouracil;
• Antipsychotics chlorpromazine and lithium;
• Anticonvulsants carbamazepine and phenytoin;
• Antibiotics isoniazid, minocycline, and nitrofurantoin (Macrodantin);
• Antirheumatic sulfasalazine;
• Diuretic hydrochlorothiazide;
• Antihyperlipidemics lovastatin and simvastatin;
• IFNs and TNF inhibitors
• ANA usually appears before symptoms; however, many of the medications mentioned above induce ANA in
patients who never develop symptoms of drug induced lupus. It is appropriate to test for ANA at the first hint of
relevant symptoms and to use test results to help decide whether to withdraw the suspect agent.
PATIENT OUTCOMES, PROGNOSIS AND SURVIVAL
• Survival in patients with SLE in the United States, Canada, Europe, and China is
approximately
• 95% at 5 years,
• 90% at 10 years,
• 78% at 20 years.
• In the United States, African Americans and Hispanic Americans with a
mestizo heritage have a worse prognosis than whites, whereas Africans in Africa
and Hispanic Americans with a Puerto Rican origin do not.
Poor prognosis (~50% mortality in 10 years) in most series is associated with (at the
time of diagnosis)-
• High serum creatinine levels (>124 μmol/L [>1.4 mg/dL]),
• Hypertension,
• Nephrotic syndrome (24-h urine protein excretion >2.6 g),
• Anemia (hemoglobin <124 g/L [<12.4 g/dL]),
• Hypoalbuminemia,
• Hypocomplementemia,
• Antiphospholipid antibodies,
• Male sex,
• Ethnicity (African American, Hispanic with mestizo heritage) and low socioeconomic
status.
Overall patient survival in SLE patients with renal transplants rejection compared to patients
with other causes of ESRD, is comparable (85% at 2 years).
Lupus nephritis occurs in approximately 10% of transplanted kidneys.
Morbidity-
• Disease associated[ primarily to chronic fatigue, arthritis, and
pain, as well as renal disease ]
• Corticosteroid associated
Mortality-
• Early[in first decade]-Active disease,renal failure and infection
• Late- Atherosclerosis [ thromboembolic events ]
THANK YOU

More Related Content

What's hot

Sle
SleSle
Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)
Qais Ali Asad
 
Systemic lupus erythematosis
Systemic lupus erythematosis Systemic lupus erythematosis
Systemic lupus erythematosis
medical education
 
Systemic sclerosis..scleroderma
Systemic sclerosis..sclerodermaSystemic sclerosis..scleroderma
Systemic sclerosis..scleroderma
Praveen Nagula
 
Systemic sclerosis
Systemic sclerosisSystemic sclerosis
Systemic sclerosis
farranajwa
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
Hirdesh Chawla
 
Sle diagnosis &amp; treatment
Sle diagnosis &amp; treatmentSle diagnosis &amp; treatment
Sle diagnosis &amp; treatment
DrSuman Roy
 
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE
SYSTEMIC LUPUS ERYTHEMATOSUS (SLESYSTEMIC LUPUS ERYTHEMATOSUS (SLE
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE
PARUL UNIVERSITY
 
Rheumatoid Arthritis: Early Diagnosis and Treatment
Rheumatoid Arthritis: Early Diagnosis and TreatmentRheumatoid Arthritis: Early Diagnosis and Treatment
Rheumatoid Arthritis: Early Diagnosis and Treatment
Dr. Swamy Venuturupalli, MD, FACR
 
Lupus Nephritis :From Basics To Practice
Lupus Nephritis :From Basics To PracticeLupus Nephritis :From Basics To Practice
Lupus Nephritis :From Basics To Practice
Yasser Matter
 
Lupus nephritis 2016
Lupus nephritis 2016Lupus nephritis 2016
Lupus nephritis 2016
drsamianik
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
KGMU LUCKNOW
 
Lupus nephritis
Lupus nephritisLupus nephritis
Lupus nephritis
University of Florida
 
systemic lupus erythematosus
systemic lupus  erythematosussystemic lupus  erythematosus
systemic lupus erythematosus
Kirsha K S
 
Toxic Epidermal Necrolysis
Toxic Epidermal NecrolysisToxic Epidermal Necrolysis
Toxic Epidermal Necrolysis
meducationdotnet
 
Vasculitis
VasculitisVasculitis
Vasculitis
drangelosmith
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
Pratap Tiwari
 
Approach to Rapidly Progressive Glomerulonephritis RPGN
Approach to Rapidly Progressive Glomerulonephritis RPGNApproach to Rapidly Progressive Glomerulonephritis RPGN
Approach to Rapidly Progressive Glomerulonephritis RPGN
Garima Aggarwal
 
Gout
GoutGout
ANCA vasculitis
ANCA vasculitisANCA vasculitis
ANCA vasculitis
Diana Girnita
 

What's hot (20)

Sle
SleSle
Sle
 
Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)
 
Systemic lupus erythematosis
Systemic lupus erythematosis Systemic lupus erythematosis
Systemic lupus erythematosis
 
Systemic sclerosis..scleroderma
Systemic sclerosis..sclerodermaSystemic sclerosis..scleroderma
Systemic sclerosis..scleroderma
 
Systemic sclerosis
Systemic sclerosisSystemic sclerosis
Systemic sclerosis
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Sle diagnosis &amp; treatment
Sle diagnosis &amp; treatmentSle diagnosis &amp; treatment
Sle diagnosis &amp; treatment
 
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE
SYSTEMIC LUPUS ERYTHEMATOSUS (SLESYSTEMIC LUPUS ERYTHEMATOSUS (SLE
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE
 
Rheumatoid Arthritis: Early Diagnosis and Treatment
Rheumatoid Arthritis: Early Diagnosis and TreatmentRheumatoid Arthritis: Early Diagnosis and Treatment
Rheumatoid Arthritis: Early Diagnosis and Treatment
 
Lupus Nephritis :From Basics To Practice
Lupus Nephritis :From Basics To PracticeLupus Nephritis :From Basics To Practice
Lupus Nephritis :From Basics To Practice
 
Lupus nephritis 2016
Lupus nephritis 2016Lupus nephritis 2016
Lupus nephritis 2016
 
Rheumatoid arthritis
Rheumatoid arthritisRheumatoid arthritis
Rheumatoid arthritis
 
Lupus nephritis
Lupus nephritisLupus nephritis
Lupus nephritis
 
systemic lupus erythematosus
systemic lupus  erythematosussystemic lupus  erythematosus
systemic lupus erythematosus
 
Toxic Epidermal Necrolysis
Toxic Epidermal NecrolysisToxic Epidermal Necrolysis
Toxic Epidermal Necrolysis
 
Vasculitis
VasculitisVasculitis
Vasculitis
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Approach to Rapidly Progressive Glomerulonephritis RPGN
Approach to Rapidly Progressive Glomerulonephritis RPGNApproach to Rapidly Progressive Glomerulonephritis RPGN
Approach to Rapidly Progressive Glomerulonephritis RPGN
 
Gout
GoutGout
Gout
 
ANCA vasculitis
ANCA vasculitisANCA vasculitis
ANCA vasculitis
 

Similar to Diagnosis and management sle

SLE -ppt.pptx
SLE -ppt.pptxSLE -ppt.pptx
SLE -ppt.pptx
MehulChoudhary18
 
SLE & APS for undergraduates: diagnosis & treatment.
SLE & APS for undergraduates: diagnosis & treatment.SLE & APS for undergraduates: diagnosis & treatment.
SLE & APS for undergraduates: diagnosis & treatment.
Faculty of Medicine, Ain Shams University
 
Lupus erythematosus. Slide Share
Lupus erythematosus. Slide ShareLupus erythematosus. Slide Share
Lupus erythematosus. Slide Share
Achu EP
 
Online lupus
Online lupusOnline lupus
Online lupus
cicou
 
4 Sle2009
4 Sle20094 Sle2009
4 Sle2009
Miami Dade
 
Systemic lupus erythmatosus
Systemic lupus erythmatosusSystemic lupus erythmatosus
Systemic lupus erythmatosus
ApoorvaMukund
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
ShahdYr
 
Autoimmune
AutoimmuneAutoimmune
Various rheumatological diseases
Various rheumatological diseasesVarious rheumatological diseases
Various rheumatological diseases
Nilesh Jadhav
 
SLE.pptx
SLE.pptxSLE.pptx
SLE.pptx
AbdulRaoof62
 
Pediatric systemic lupus erythematosus
Pediatric systemic lupus erythematosusPediatric systemic lupus erythematosus
Pediatric systemic lupus erythematosus
CSN Vittal
 
SLE
SLESLE
Systemic Lupas Eruthmatosus
Systemic Lupas EruthmatosusSystemic Lupas Eruthmatosus
Systemic Lupas Eruthmatosus
Fardan Qadeer
 
SLE.pdf
SLE.pdfSLE.pdf
SLE.pdf
AhmedAzzan2
 
SLE.pptx
SLE.pptxSLE.pptx
SLE.pptx
MahnoorM5
 
Connective tissue diseases
Connective tissue diseases Connective tissue diseases
Connective tissue diseases
dr. suresh kumar
 
SLE by DRMAGDI SASI 2016
SLE by DRMAGDI SASI 2016SLE by DRMAGDI SASI 2016
SLE by DRMAGDI SASI 2016
cardilogy
 
Lupus
LupusLupus
Systemic Lupus Erythematosus
Systemic Lupus ErythematosusSystemic Lupus Erythematosus
Systemic Lupus Erythematosus
Bardia Farivar
 
Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus
LupusNY
 

Similar to Diagnosis and management sle (20)

SLE -ppt.pptx
SLE -ppt.pptxSLE -ppt.pptx
SLE -ppt.pptx
 
SLE & APS for undergraduates: diagnosis & treatment.
SLE & APS for undergraduates: diagnosis & treatment.SLE & APS for undergraduates: diagnosis & treatment.
SLE & APS for undergraduates: diagnosis & treatment.
 
Lupus erythematosus. Slide Share
Lupus erythematosus. Slide ShareLupus erythematosus. Slide Share
Lupus erythematosus. Slide Share
 
Online lupus
Online lupusOnline lupus
Online lupus
 
4 Sle2009
4 Sle20094 Sle2009
4 Sle2009
 
Systemic lupus erythmatosus
Systemic lupus erythmatosusSystemic lupus erythmatosus
Systemic lupus erythmatosus
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Autoimmune
AutoimmuneAutoimmune
Autoimmune
 
Various rheumatological diseases
Various rheumatological diseasesVarious rheumatological diseases
Various rheumatological diseases
 
SLE.pptx
SLE.pptxSLE.pptx
SLE.pptx
 
Pediatric systemic lupus erythematosus
Pediatric systemic lupus erythematosusPediatric systemic lupus erythematosus
Pediatric systemic lupus erythematosus
 
SLE
SLESLE
SLE
 
Systemic Lupas Eruthmatosus
Systemic Lupas EruthmatosusSystemic Lupas Eruthmatosus
Systemic Lupas Eruthmatosus
 
SLE.pdf
SLE.pdfSLE.pdf
SLE.pdf
 
SLE.pptx
SLE.pptxSLE.pptx
SLE.pptx
 
Connective tissue diseases
Connective tissue diseases Connective tissue diseases
Connective tissue diseases
 
SLE by DRMAGDI SASI 2016
SLE by DRMAGDI SASI 2016SLE by DRMAGDI SASI 2016
SLE by DRMAGDI SASI 2016
 
Lupus
LupusLupus
Lupus
 
Systemic Lupus Erythematosus
Systemic Lupus ErythematosusSystemic Lupus Erythematosus
Systemic Lupus Erythematosus
 
Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus
 

Recently uploaded

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Donc Test
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
MGM SCHOOL/COLLEGE OF NURSING
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
Dr. Jyothirmai Paindla
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
ABDOMINAL TRAUMA in pediatrics part one.
ABDOMINAL TRAUMA in pediatrics part one.ABDOMINAL TRAUMA in pediatrics part one.
ABDOMINAL TRAUMA in pediatrics part one.
drhasanrajab
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
Earlene McNair
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
SwisschemDerma
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Swastik Ayurveda
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
chandankumarsmartiso
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
SwisschemDerma
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ayurveda ForAll
 

Recently uploaded (20)

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxIdentification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
 
A Classical Text Review on Basavarajeeyam
A Classical Text Review on BasavarajeeyamA Classical Text Review on Basavarajeeyam
A Classical Text Review on Basavarajeeyam
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
ABDOMINAL TRAUMA in pediatrics part one.
ABDOMINAL TRAUMA in pediatrics part one.ABDOMINAL TRAUMA in pediatrics part one.
ABDOMINAL TRAUMA in pediatrics part one.
 
Chapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptxChapter 11 Nutrition and Chronic Diseases.pptx
Chapter 11 Nutrition and Chronic Diseases.pptx
 
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Top Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in IndiaTop Effective Soaps for Fungal Skin Infections in India
Top Effective Soaps for Fungal Skin Infections in India
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 
Top 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in IndiaTop 10 Best Ayurvedic Kidney Stone Syrups in India
Top 10 Best Ayurvedic Kidney Stone Syrups in India
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptxVestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
 
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
 
Top-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India ListTop-Vitamin-Supplement-Brands-in-India List
Top-Vitamin-Supplement-Brands-in-India List
 
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachIntegrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
 

Diagnosis and management sle

  • 1. DIAGNOSIS AND MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS A PRESENTATION BY DR. ASHVINI K. LOMROD UNDER THE GUIDANCE OF DR. C.K. MEENA SIR JLN MEDICAL COLLEGE, AJMER
  • 2. Systemic+ Lupus+ Erythematosus Systemic - The disease can affect organs and tissues throughout the body. Lupus [ Latin for wolf ] It refers to the rash that was thought to resemble a wolf bite. Erythematosus [ Greek word for red ] – It refers to the color of the rash.
  • 3. DEFINITION •A systemic autoimmune disease with relapsing and remitting course that can affect almost any organ system in which organs and cells undergo damage mediated by tissue binding autoantibodies and immune complexes.
  • 5. ➢ Gender – 90% women(women to men ratio 9:1) in child bearing age. Flares also become some what less common after menopause in women have chronic SLE. Female sex is permissive for SLE because: - Hormone effects - Genes on X-chromosome -Epigenetic differences between genders Estradiol binds to receptors on T & B lymphocytes increasing activation & survival of these cells, thus favouring prolonged immune response. So women are exposed to estrogen containing OCP and hormone replacement therapy have an increased risk of developing SLE. People with more X-chromosomes(XXX karyotypes,Klinefelter’s syndrome) have a significant increased risk for SLE.
  • 6. ➢ Age – 15-44 yrs are commonly affected. ➢Race & Ethnicity – More common in urben than rural areas. Highest prevalence is in black women and lowest is in white men. ➢ Family History - A brother or sister of a patient with the disorder has 20 times the risk as someone without an immediate family member with SLE.
  • 7. ➢Environmental Triggers – Sunlight, cold, fatigue, stress, chemicals and certain drugs. *Sunlight : Ultraviolet rays (UVB or UVA) Shorter UVB wavelengths cause the most harm. *Viruses : EBV ( The cause of mononucleosis) *Smoking : May increase the risk for skin and kidney problems in women who have the disease. *Tobacco *Chemicals: Occupational exposure to crystalline silica as a possible trigger. Some prescription medications are associated with a temporary lupus syndromes (drug-induced lupus),which resolves after these drugs are stopped. ☻ Drinking alcohol(2 glasses of wine a week or ½ of an alcoholic drink daily) reduces the risk of SLE.
  • 8. * Hormone Replacement Therapy : increases the risk for blood clots and heart problems as well as breast cancer. Guidelines recommend HRT the lowest possible dose for the shortest possible time. Women with SLE who have active disease, antiphospholipid Antibodies or a history of blood clots or heart disease should not use HRT. * Oral Contraceptives : Caution against taking OCPs( Estrogen could trigger lupus flare-ups).However, recent evidence indicate that OCs are safe, at least for women with inactive or stable lupus. Lupus can cause complications in its early stages. The estrogen in OCs increase the risk for blood clots.(Risk particularly for women with antiphospholipid syndrome)
  • 10. ➢ SLE - The most common type and is the type of lupus that can lead to serious systemic complications. ➢ Cutaneous lupus erythematosus - Confined to the skin and does not affect other parts of the body. About 10% of people with this type of lupus go on to develop SLE. ➢ Discoid lupus erythematosus - A type of cutaneous lupus that produces a potentially scarring disc shaped rash on the face, scalp or ears.
  • 11. ➢ Drug-induced lupus - Temporary and mild form of lupus due to some drugs like Hydralazine, ACE inhibitors, and calcium channel blockers, hydrochlorothiazide. Symptoms resolve once the medication is stopped. ➢ Neonatal lupus - A rare condition that sometimes affects infants born to mothers who have SLE. Babies with neonatal lupus are born with skin rash, liver problems, and low blood counts and may develop heart problems.
  • 13. Role of Genetics and Environment ➢Environment • Cell damage by environmental triggers causes apoptosis that leads to release of apoptotic bodies+parts of nucleus [ now exposed to other parts of body ] ➢ Genetics – Susceptibility genes and their effect on immune system. • loss of self tolerance [ immune system recognizes parts of nucleus as self antigens ] • Self Ag presentation by DCs, • Defective complement system, • Impaired clearance of apoptotic cells • Aberrant lymphocyte activity[unregulated T cell dependent B cell activation] • Production of autoantibodies
  • 14. • Antigen-Antibody complexes / Immune Complexes deposition in various body tissues [ basement membranes ] results – Local inflammation – Local complement activation – Local apoptosis – Positive feedback loop • DNA is the main antigen for which antibodies are formed • IgG is the most “pathogenic” because it forms intermediate sized complexes that can get to the small places and block them • Injury is caused by Mainly deposition of immune complexes and Binding of antibodies to various cells and tissues. • In most patients, autoantibodies are present for a few years before the first clinical symptom appears
  • 15. Ag, antigen; C1q, complement system; C3, complement component; CNS, central nervous system; DC, dendritic cell; EBV, Epstein-Barr virus; HLA, human leukocyte antigen; FcR, immunoglobulin Fc-binding receptor; IL, interleukin; MCP, monocyte chemotactic protein; PTPN, phosphotyrosine phosphatase; UV,ultraviolet.
  • 18. Constitutional • Fatigue – Mild to extreme • Malaise • Fever – any pattern • Anorexia • Weight loss • lymphadenopathy • Arthralgia
  • 19. Musculoskeletal • Arthralgia , myalgia • Polyarthritis [ 2 or more peripheral joint ] - Intermittent,mild to disabling,soft tissue swelling, tenderness,Nonerosive,MC in hands,wrists and knees • Joint deformities (hands and feet)-In 10% cases ,erosions can be identified on ultrasound (rarely on x-rays) • Myopathy /myositis • Ischemic necrosis of bone “rhupus”-some patients of SLE have rheumatoid like arthritis with erosions and fulfill criteria for both RA and SLE so may be coded having both diseases
  • 21. Cutaneous • Photosensitivity-skin rash on Sun exposed areas due to sunlight • Malar rash –MC acute SLE rash-photosensitive,slightly raised erythema,occasionaly scally, on the face(butterfly rash-malar eminences and nasal bridge)but sparing nasolabialfold, ears,chin,neck and chest,upper backand extensor surfaces of the arms • Discoid rash (DLE)-MC chronic dermatitis in lupus,lesions roughly circular with slightly raised ,scaly hyperpigmented erythematous rims and depigmented,atrophic centers (permanently damaged dermal appendages) • Subacute cutaneous lupus • Oral lesions-Erythema of palate,tongue and oral mucosa,papules,vesicles and petechiae.oral or nasopharyngial ulceration usually painless • Alopacia • Others-urticaria, • Vasculitis rash • Raynodes phenomena
  • 24. Photosensitive systemic lupus erythematosus (SLE) rashes typically occur on the face or extremities which are sun exposed regions. Although the interphalangeal space are affected, the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints are spared.
  • 25.
  • 26. Hematologic • Anemia of chronic disease-most frequent • Hemolytic anemia • Leukopenia (<4000/micro litre) • Lymphopenia (<1500/micro litre) • Throbocytopenia (<1,00,000/micro litre) • Lympadenopathy • Splenomegaly
  • 27. Neurologic • Cognitive disorder - MC manifestation of diffuse CNS lupus • Mood disorder • Headache • Seizures • Mono-,polyneuropathy • Stroke,TIA • Acute confusional state or movement disorder • Aseptic meningitis , myelopathy
  • 28. PULMONARY • MC-Pleuritis with or without pleural effusion – Chest pain • Lupus pneumonitis • Interstitial fibrosis • Pulmonary hypertension, • ARDS, intraalveolar Hemorrhage • Shrinking lung syndrome
  • 29. CARDIAC • Pericarditis-most frequent cardiac manifestation • Myocarditis • Fibrinous endocarditis of libman-sacks (valvular vegetations) • Accelerated atherosclerosis-10 times higher mortality • Coronary artery disease • Aortic insufficiency- MC valvular lesion
  • 30. Renal • 50 % of lupus pts will have kidney involvement in their life ,of these 50 % will have serious kidney disease • Persistent proteinuria > 0.5 grams / 24 hrs (or greater than 3+), cellular casts ( may be red cells ,hemoglobin,granular, tubular,mixed) • Nephritis (Lupus nephritis) –the most serious manifestation and also predict outcome (prognosis) • Renal Failure because of Glomerulonephritis is the leading cause of death among lupus patients. • Nephrotic syndrome • ESRD
  • 31. GIT • Nonspecific – Nausea, vomitting, diarrhea • Diffuse abdominal pain-autoimmune peritonitis and/or intestinal vasculitis • Abnormal liver enzymes (more often due to therapy than to SLE itself) • Mesenteric Vasculitis • Sepsis and bleeding
  • 32. Thromboembolic events Patients of Antiphospholipid syndrome due to hypercoagulable state more prone to clots [ venous or arterial ] that can leads to • Deep vein thrombosis • Hepatic vein thrombosis • Stroke • Myocardial infarction
  • 33. Ocular • Common but less serious - Sicca syndrome Conjunctivitis Episcleritis • Serious manifestations - Retinal vasculitis Optic neuritis • Fundoscopy shows sheathed, narrow retinal arterioles and white hard exudate called ‘Cytoid body’
  • 34.
  • 35.
  • 36.
  • 38.
  • 39.
  • 40.
  • 41. LN-Treatment In general, class III and IV disease, as well as class V accompanied by III or IV disease, should be treated with aggressive immunosuppression if possible, because there is a high risk for end-stage renal disease (ESRD) if patients are untreated or undertreated. In contrast, treatment for lupus nephritis is not recommended in patients with class I or II disease or with extensive irreversible changes.
  • 42. INVESTIGATIONS AIMS • Diagnosis of SLE • Course of the disease • Adverse effects of therapies
  • 43. LABORATORY TESTS • Antinuclear antibodies [ANA]-Sensitive but not specific • Anti -ds DNA-[ More specific ], targets double-stranded DNA, seen during active disease • 4 RNA associated antibodies - Anti-Sm [Smith] –[ More specific ]Targets ribonucleoproteins Anti Ro /SSA- antibody Anti La/SSB- antibody Anti –RNP • Antiphopholipid antibody- [Less specific to Lupus] Targets protein bound to phospholipid Lupus anticoagulent [ Lupus antibody ] Anti-B2 glycoprotein 1 AB Anti-cardiolipin
  • 44. • Coombs test- Hemolytic anemia . • Complete blood count-Hemolytic anemia with reticulocytosis Leukopenia-less than 4,000 / cu mm on 2 or more occasions Lymphopenia-less than 1,500 / cu mm on 2 or more occasions Thrombocytopenia-less than 100,000 /cu mm , in the absence of offending drugs • Erythrocyte sedimentation rate • RFT,LFT ,Lipid profile • C-reactive protein • Urine routine and microscopy and 24 hrs protein and creatinine estimation
  • 45. • Complement levels [ C3 and C4 ] - Decreased (C3 level < 5.5 mg/dl) • Chest radiography and chest CT scanning- ILD, pneumonitis, pulmonary emboli, alveolar haemorrhages • Joint radiograpy-periarticular osteopenia and soft tissue swelling without erosions • Echocardiography-pericardial effusion • ↑ ESR, ↑ anti ds-DNA and ↓C3 may indicate disease ‘flare’
  • 46. Skin Biopsy LUPUS BAND TEST (60%) Deposition of Ig at the dermoepidermal junction (DEJ), injury to basal keratinocytes, and inflammation dominated by T lymphocytes in the DEJ and around blood vessels and dermal appendages. Clinically unaffected skin may also show Ig deposition at the DEJ
  • 47. Renal biopsy • In the recent Systemic Lupus International Collaborating Clinic (SLICC) criteria for classification of SLE, a diagnosis can be established on the basis of renal histology alone without meeting additional criteria . • The pattern and severity of injury are important in diagnosis and in selecting the best therapy. • Recommended for every SLE patient with any clinical evidence of nephritis • Not recommended as a screening test
  • 48. Histologic abnormalities in blood vessels • Leukocytoclastic vasculitis is most common. • Not specific for SLE but may indicate active disease Lymph node biopsies • Nonspecific diffuse chronic inflammation. • Usually performed to rule out infection or malignancies.
  • 49.
  • 50. MANAGEMENT • There is no cure for SLE and complete sustained remissions are rare so management aims to induce remissions of acute flares , maintenance therapy and thereby preventing organ damage • Many patients with SLE have “flares”, in which symptoms suddenly worsen and then settle down for long periods of time.
  • 51.
  • 52. Conservative management • NSAIDs, salicylates (Ecotrin a and St. Joseph’s aspirin approved by FDA for use in SLE ) for arthritis / arthralgia- Doses toward upper limit of recommended range usually required • Antimalarials(HCQ,CQ,quinacrine)-for dermatitis, arthritis, fatigue • Systemic glucocorticosteroids( low dose) • Belimumab • lupus dermatitis-topical sunscreens [ SPF 15 at least ; 30+ preferred],antimalarials, topical glucocorticoids and/or tacrolimus and systemic glucocorticoids with or without mycophenolate for severe or unresponsive cases
  • 53. Life threatening SLE • Systemic glucocorticoids • Cytotoxic/immunosuppressive therapy
  • 54. Systemic glucocorticoids • MPS and Prednisolone MPS 500-1000 mg IV over 1 hour OD for 3 days followed by 0.5 - 1 mg/kg per day prednisolone PO Currently 0.5 - 1 mg/kg per day prednisolone PO for 4-6 weeks therefore tappered as soon as condition improves usually to a dose 5-10 mg daily 0.07–0.3 mg/kg prednisolone per day or qod for milder disease
  • 55. Cytotoxic/immunosuppressive therapy ➢ Methotrexate [for dermatitis, arthritis] 10–25 mg once a week, PO or SC, with folic acid; decrease dose if CrCl<60 mL/min ➢ Cyclophosphamide • IV Low dose : 500 mg every 2 weeks for 6 doses maintenance with MMF or AZA. High dose: 7–25 mg/kg q month × 6; consider mesna administration with dose • Oral 1.5–3 mg/kg per day; decrease dose for CrCl <25 mL/min
  • 56. • Mycophenolate MMF: 2–3 g/d PO for induction therapy, 1–2 g/d for maintenance therapy; max 1 g bid if CrCl <25 mL/min MPA: 360–1080 mg bid; caution if CrCl<25 mL/min • Azathioprine 2–3 mg/kg per day PO for induction; 1–2 mg/kg per day for maintenance; decrease frequency of dose if CrCl <50 mL/min • Belimumab 10 mg/kg IV wks 0, 2, and 4, then monthly • Rituximab [ for patients resistant to above therapies ] 375 mg/m2 q wk × 4 or 1 g q 2 wks × 2
  • 57. SERIOUS OR COMMON ADVERSE EFFECTS OF DRUGS USED IN SLE • NSAIDS-aseptic meningitis,elevated liver enzymes,decreased renal functions,vasculitis of skin,MI,ototoxicity,tinitus,allergic reactions,dermatitis,gi events,ARF,edema,HTN • Topical GC-skin atrophy,contact dermatitis,,folliculitis,hypopigmentation,infection • Topical sunscreens-contact dermatitis • HCQ-retinal damage,cornial opacity myopathy ,neuropathy • MTX-megaloblastic anemia at low doses and bone marrow suppression at high doses • GC-infections,HTN,hyperglycemia,hypokalemia,allergic reactions,cushingoid changesCHF,fragile skin,menstrual abnormalities,osteoporosis
  • 58. • MPS-same as gc; anaphylaxis • Cyclophosphamide bone marrow suppression pancytopenia,hemorragic cystitis,ovarian and testicular failure • Mycophenolate –Vomiting diarrhoea and leukopenia • Azathioprine –bone marrow suppression • Rituximab - Infection (including PML), infusion reactions, headache, arrhythmias, allergic responses • Belimumab - Infusion reactions, allergy, infections probable
  • 59. Lifestyle changes to help cope with SLE. • Get plenty of rest (fatigue is another common SLE symptom) • Salt restriction [ if HTN ] , avoid fat [ for hyperlipidaemia ] , calcium supplements with steroid therapy • Engage in regular light-to-moderate exercise to help fight fatigue and heart disease, and to keep joints flexible • Avoid excessive sunlight exposure, and wear sunscreen (ultraviolet light is the one of the main triggers of flares) • Don't smoke and avoid exposure to second-hand tobacco smoke
  • 60. PREVENTIVE THERAPIES Prevention of complications of SLE and its therapy • Suppressing recurrent urinary tract infections. • Providing appropriate vaccinations [ the administration of influenza and pneumococcal ]. [ Vaccination with attenuated live viruses is generally discouraged in patients who are immunosuppressed ]. • Prevention of osteoporosis . [ Postmenopausal women can be protected from steroid-induced osteoporosis with either bisphosphonates or denosumab. Safety of long-term use of these strategies in women is not well established ]. • Control of hypertension • Prevention strategies for atherosclerosis monitoring and treatment of dyslipidemias management of hyperglycemia and obesity.
  • 61. DIFFERENTIAL DIAGNOSIS • Chronic fatigue syndrome • Undifferentiated connective tissue disease • Primary Sjogren`s syndrome • Primary antiphospholipid syndrome • Fibromyalgia with positive ANA • Idiopathic thrombocytopenic purpura • Drug-induced lupus • Early RA • Systemic vasculitis
  • 62. SLE & PREGNANCY • Increases the risk of spontaneous abortion, IUD, preeclampsia,IUGR and preterm birth • Prognosis best for both mother and child when SLE is quiescent for at least 6 months before the pregnancy and mothers renal function stable and normal or near normal • Lupus nephritis can get worse during pregnancy • In general pregnancy does not cause flares of SLE • When flares do develop ,they often occur during the first or second trimester or during first few months after delivery
  • 63. SPECIAL CONDITIONS IN SLE THAT MAY REQUIRE ADDITIONAL OR DIFFEENT THERAPY Crescentic Lupus Nephritis The presence of cellular or fibrotic crescents in glomeruli with proliferative glomerulonephritis indicates a worse prognosis Most authorities currently recommend that high-dose cyclophosphamide is the induction therapy of choice, in addition to high-dose glucocorticoids.
  • 64. Membranous Lupus Nephritis Immunosuppression is not recommended unless proteinuria is in the nephrotic range (although treatment with ACE inhibitors or angiotensin II receptor blockers is recommended). In those patients, recent prospective controlled trials suggest that alternate- day glucocorticoids plus cyclophosphamide or mycophenolate mofetil or cyclosporine are all effective in the majority of patients in reducing proteinuria.
  • 65. Pregnancy and Lupus • Fertility rates for men and women with SLE are probably normal. • Rate of fetal loss is increased (approximately two- to threefold) in women with SLE. • Fetal demise is higher in mothers with high disease activity, antiphospholipid antibodies, and/or active nephritis. • Suppression of disease activity can be achieved by administration of systemic glucocorticoids. • Glucocorticoids [ Pregnancy category A (no evidence of teratogenicity in human studies)] • Cyclosporine, tacrolimus, and rituximab [category C (may be teratogenic in animals but no good evidence in humans) ]; • Azathioprine, hydroxychloroquine, mycophenolate mofetil, and cyclophosphamide [category D (there is evidence of teratogenicity in humans, but benefits might outweigh risks in certain situations) ]; • Methotrexate [ category X (risks outweigh benefits)].
  • 66. • Therefore, active SLE in pregnant women should be controlled with hydroxychloroquine and, if necessary, prednisone/prednisolone at the lowest effective doses for the shortest time required. • Azathioprine may be added if these treatments do not suppress disease activity. The cardiac manifestations can be life-threatening. Recent evidence shows that hydroxychloroquine treatment of an anti-Ro-positive mother whose infant develops congenital heart block significantly reduces the chance that subsequent fetuses will develop heart block ,also with dexamethasone A small proportion develops severe flares requiring aggressive glucocorticoid therapy or early delivery. Poor maternal outcomes are highest in women with active nephritis or irreversible organ damage in kidneys, brain, or heart.
  • 67.
  • 68. Lupus and Antiphospholipid Syndrome (APS) • Patients with SLE who have venous or arterial clotting and/or repeated fetal losses and at least two positive tests for antiphospholipid antibodies have APS • Should be managed with long-term anticoagulation . • A target international normalized ratio (INR) of 2.0–2.5 is recommended for patients with one episode of venous clotting. • An INR of 3.0–3.5 is recommended for patients with recurring clots or arterial clotting, particularly in the CNS. • Recommendations are based on both retrospective and prospective studies of post treatment clotting events and adverse effects from anticoagulation.
  • 69. Microvascular Thrombotic Crisis (Thrombotic Thrombocytopenic Purpura, Hemolytic-Uremic Syndrome) • This syndrome of hemolysis, thrombo cytopenia, and microvascular thrombosis in kidneys, brain, and other tissues carries a high mortality rate and occurs most commonly in young individuals with lupus nephritis. • The most useful laboratory tests are identification of schistocytes on peripheral blood smears, elevated serum levels of lactate dehydrogenase, and antibodies to ADAMS13 • Plasma exchange or extensive plasmapheresis is usually life-saving; most authorities recommend concomitant glucocorticoid therapy; there is no evidence that cytotoxic drugs are effective.
  • 70. Lupus Dermatitis • Minimize exposure to ultraviolet light [ appropriate clothing and sunscreens ] . • Topical glucocorticoids and antimalarials (such as hydroxychloroquine) reduces lesion severity in most patients and are relatively safe. • Systemic treatment with retinoic acid is a useful strategy in patients with inadequate improvement on topical glucocorticoids and antimalarials; adverse effects are potentially severe (particularly fetal abnormalities), • Extensive, pruritic, bullous, or ulcerating dermatitis usually improve promptly after institution of systemic glucocorticoids; tapering may be accompanied by flare of lesions, thus necessitating use of a second medication such as hydroxychloroquine, retinoids, or cytotoxic medications such as methotrexate, azathioprine, or mycophenolate mofetil. • Topical tacrolimus - In therapy-resistant lupus dermatitis [possible increased risk for malignancies ] dapsone or thalidomide [ the extreme danger of fetal deformities ]
  • 71. EXPERIMENTAL THERAPIES ➢ Highly targeted experimental therapies targeting • (1) activated B lymphocytes with anti-CD22 or TACI-Ig, • (2) inhibition of IFN-α, • (3) inhibition of B/T cell second signal coactivation with CTLA-Ig, • (4) inhibition of innate immune activation via TLR7 or TLR7 and 9, • (5) induction of regulatory T cells with peptides from immunoglobulins or autoantigens; • (6) suppression of T cells, B cells, and monocyte/macrophages with laquinimod; and • (7) inhibition of lymphocyte activation by blockade of Jak/Stat. A few studies have used vigorous untargeted immunosuppression with high dose cyclophosphamide plus anti-T cell strategies, with rescue by transplantation of autologous hematopoietic stem cells for the treatment of severe and refractory SLE. One U.S. report showed an estimated mortality rate over 5 years of 15% and sustained remission in 50%.
  • 72. DRUG-INDUCED LUPUS • A syndrome of positive ANA associated with symptoms such as fever, malaise, arthritis or intense arthralgias/myalgias, serositis, and/or rash, during therapy with certain medications and biologic agents. • Predominant in whites, has less female predilection than SLE. • Rarely involves kidneys or brain. • Rarely associated with anti-dsDNA. • Commonly associated with antibodies to histones. • Usually resolves over several weeks after discontinuation of the offending medication.
  • 73. The most frequent drugs – • Antiarrhythmics procainamide, disopyramide, and propafenone; • Antihypertensive hydralazine; • Angiotensin-converting enzyme inhibitors and beta blockers; • Antithyroid propylthiouracil; • Antipsychotics chlorpromazine and lithium; • Anticonvulsants carbamazepine and phenytoin; • Antibiotics isoniazid, minocycline, and nitrofurantoin (Macrodantin); • Antirheumatic sulfasalazine; • Diuretic hydrochlorothiazide; • Antihyperlipidemics lovastatin and simvastatin; • IFNs and TNF inhibitors • ANA usually appears before symptoms; however, many of the medications mentioned above induce ANA in patients who never develop symptoms of drug induced lupus. It is appropriate to test for ANA at the first hint of relevant symptoms and to use test results to help decide whether to withdraw the suspect agent.
  • 74. PATIENT OUTCOMES, PROGNOSIS AND SURVIVAL • Survival in patients with SLE in the United States, Canada, Europe, and China is approximately • 95% at 5 years, • 90% at 10 years, • 78% at 20 years. • In the United States, African Americans and Hispanic Americans with a mestizo heritage have a worse prognosis than whites, whereas Africans in Africa and Hispanic Americans with a Puerto Rican origin do not.
  • 75. Poor prognosis (~50% mortality in 10 years) in most series is associated with (at the time of diagnosis)- • High serum creatinine levels (>124 μmol/L [>1.4 mg/dL]), • Hypertension, • Nephrotic syndrome (24-h urine protein excretion >2.6 g), • Anemia (hemoglobin <124 g/L [<12.4 g/dL]), • Hypoalbuminemia, • Hypocomplementemia, • Antiphospholipid antibodies, • Male sex, • Ethnicity (African American, Hispanic with mestizo heritage) and low socioeconomic status. Overall patient survival in SLE patients with renal transplants rejection compared to patients with other causes of ESRD, is comparable (85% at 2 years). Lupus nephritis occurs in approximately 10% of transplanted kidneys.
  • 76. Morbidity- • Disease associated[ primarily to chronic fatigue, arthritis, and pain, as well as renal disease ] • Corticosteroid associated Mortality- • Early[in first decade]-Active disease,renal failure and infection • Late- Atherosclerosis [ thromboembolic events ]